Kaplan–Meier survival analyses revealed that Cbl-b expression was significantly associated with better OS (p = 0.013) and DFS (p = 0.016) in patients with breast cancer, though the median OS and DFS were not reached at the last follow-up of November 2017 (Figures 2A,B). Here, CBLB is linked to breast carcinoma.